We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lung Cell Protein Triggers a Dangerous Immune Response

By LabMedica International staff writers
Posted on 23 Aug 2016
Print article
Image: Teneema Kuriakose, Ph.D., a postdoctoral research associate, and Thirumala-Devi Kanneganti, Ph.D. Immunologists have identified the protein trigger in the body’s quick-reaction innate immune system that specifically recognizes the influenza virus in infected cells and triggers their death (Photo courtesy of St. Jude Children’s Research Hospital).
Image: Teneema Kuriakose, Ph.D., a postdoctoral research associate, and Thirumala-Devi Kanneganti, Ph.D. Immunologists have identified the protein trigger in the body’s quick-reaction innate immune system that specifically recognizes the influenza virus in infected cells and triggers their death (Photo courtesy of St. Jude Children’s Research Hospital).
A protein in the cytoplasm of lung cells helps protect against viral infection, but following invasion by the influenza virus, the same protein stimulates the immune system to overact, which can lead to inflammation or pneumonia.

Individuals infected with influenza become ill not only because of the presence of virus but also because of the inflammatory immune response triggered by reaction to the virus.

The Z-DNA binding protein 1 (ZBP1, also known as DNA-dependent activator of IFN regulatory factors) gene encodes a Z-DNA binding protein. Z-DNA formation is a dynamic process, largely controlled by the amount of supercoiling. ZBP1 recognizes DNA in the cytoplasm as an antiviral mechanism. Viral life cycles often include steps where DNA is exposed in the cytoplasm. DNA is normally contained in the nucleus of a cell, and therefore cells use proteins like ZBP1 as an indicator of a viral infection. Once ZBP1 is activated, it increases the production of antiviral cytokines such as interferon-beta (INF-beta).

Investigators at St. Jude Children's Research Hospital (Memphis, TN, USA) initially demonstrated that ZBP1-mediated sensing of the influenza A virus (IAV) proteins NP and PB1 triggered cell death and inflammatory responses.

In order to further clarify the role of ZPB1 in flu infection, they used genetic engineering techniques to create a line of mice that lacked the ZBP1 gene.

The investigators reported in the August 12, 2016, online edition of the journal Science Immunology that mice lacking ZBP1 showed an increased viral load and delayed recovery. On the other hand, these mice had decreased inflammation and less epithelial damage than control animals.

"Our discovery was totally unexpected," said senior author Dr. Thirumala-Devi Kanneganti, an immunologist at St. Jude Children's Research Hospital. "We never thought we would actually identify this molecule to be important in influenza viral infection, because there is no DNA stage in the influenza life cycle. ZBP1 does an amazing job of killing off infected cells. But it would be very useful to modulate ZBP1 in later stages of the infection, when the uncontrolled inflammation causes damage."

"Since the pathology that we saw in the mice matches what is seen in humans, we will now explore translating these findings to humans," said Dr. Kanneganti. "If we can somehow modulate the activation of this pathway, that will help to decrease the exaggerated inflammatory response that causes mortality during influenza infection. We have shown that these molecules are important in viral infections, but now we want to test their role in other inflammatory conditions. ZBP1 is likely not dedicated to attacking only the influenza virus. Maybe it also plays other roles, and if we fully understand those roles, we can learn how to manipulate immune responses."

Related Links:
St. Jude Children's Research Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.